ALSO NOTED: Procognia, Teva to collaborate; FDA questions Trasylol; and much more...

> In a new collaboration deal, the UK's Procognia will give Teva access to its proprietary glycoanalysis technology as the cooperate on the development of two drug candidates. Teva will fund the work and pay an unspecified set of milestones. Report

> FDA staffers are questioning the deaths and allergic reactions seen in the testing of Bayer's heart surgery drug Trasylol. Report

> The backers of embryonic stem cell research in Michigan have launched a new organization that they hope will eventually overturn a state ban on buying embryonic stem cells from in vitro fertilization clinics. Report

> A scientific consortium led by the University of North Carolina in Chapel Hill will receive a $21.3 million grant to research new drugs for African sleeping sickness (Trypanosomiasis) and Leishmania. Release

> Active Biotech is touting positive results from a Phase I study of a prostate cancer therapy. A Phase II/III study is scheduled for next year. Report

> The FDA has accepted Vernalis' NDA for Frova, a therapy for preventing menstrual migraine. Report

And Finally… A new study shows that Vitamin D can reduce the risk of pancreatic cancer. Article

Suggested Articles

Dewpoint Therapeutics aims to advance research in one of the more mysterious cell organelles: biomolecular condensates.

The FDA slapped a partial clinical hold on the phase 2/3 study of Inovio’s COVID-19 vaccine because it has “additional questions” about the trial.

Preclinical inflammatory disease biotech Ilias Biologics has grabbed a $20.6 million funding round as it eyes a 2021 human test of its leading asset.